Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Shares Outstanding (Weighted Average) (2016 - 2025)

Regenxbio has reported Shares Outstanding (Weighted Average) over the past 12 years, most recently at $869603.0 for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $869603.0 for Q4 2025, down 98.24% from a year ago — trailing twelve months through Dec 2025 was $869603.0 (down 98.24% YoY), and the annual figure for FY2025 was $869603.0, down 34.36%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $869603.0 at Regenxbio, down from $51.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for RGNX hit a ceiling of $51.7 million in Q3 2025 and a floor of $41819.0 in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $42.9 million (2021), compared with a mean of $27.8 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): tumbled 99.9% in 2022 and later soared 101155.13% in 2023.
  • Regenxbio's Shares Outstanding (Weighted Average) stood at $42.4 million in 2021, then grew by 1.68% to $43.2 million in 2022, then increased by 1.35% to $43.7 million in 2023, then rose by 13.2% to $49.5 million in 2024, then crashed by 98.24% to $869603.0 in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $869603.0 (Q4 2025), $51.7 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.